Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

tremelimumab 1durvalumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignancy × Clear all
NCT07123129 2026-01-30

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Recruiting
200 enrolled

Advanced Malignancy

NCT03875157 2023-02-27

Study of IBI318 in Participants With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
103 enrolled

Advanced Malignancy

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
93 enrolled

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡